When 505(j) Meets 505(p)
In creating Risk Evaluation and Mitigation Strategies, Congress made an effort to ensure that the new mechanism would not preclude the launch of generic versions of a product covered by a REMS. The text of the statute related to ANDAs is below. Interestingly, the word "shared" appears omitted in description of a single system in section (i).
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth